Petito v. AH Robins Co., Inc.

750 So. 2d 103, 1999 WL 1221653
CourtDistrict Court of Appeal of Florida
DecidedDecember 22, 1999
Docket98-3274
StatusPublished
Cited by31 cases

This text of 750 So. 2d 103 (Petito v. AH Robins Co., Inc.) is published on Counsel Stack Legal Research, covering District Court of Appeal of Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Petito v. AH Robins Co., Inc., 750 So. 2d 103, 1999 WL 1221653 (Fla. Ct. App. 1999).

Opinion

750 So.2d 103 (1999)

Joseph PETITO and Terry Stubbs, Appellants,
v.
A.H. ROBINS COMPANY, INC., a Delaware corporation, Zenith Goldline Pharmaceutical, Inc., a Florida corporation, Appellees.

No. 98-3274.

District Court of Appeal of Florida, Third District.

December 22, 1999.
Rehearing Denied February 16, 2000.

*104 Robles & Gonzalez and Ervin Gonzalez and Raymond W. Valori, Miami; Leeds & Colby, Miami; L. Dianne Mason, Coral Gables, for appellants.

Cooney, Mattson, Lance, Blackburn, Richards & O'Connor; Arnold & Porter and Steven P. Lockman and Ellen Steury and Bruce M. Chadwick, Washington, DC; Sterns Weaver Miller Weissler Alhadeff & Sitterson and Martin B. Woods, Ft. Lauderdale; Lester, Schwab, Katz & Dwyer and Frederick H. Fern, Millburn, NJ, for appellees.

Before SCHWARTZ, C.J., and NESBITT, and SORONDO, JJ.

NESBITT, J.

The instant case presents an issue which several other courts have recently confronted, but which no Florida court has directly addressed: whether or not Florida recognizes a cause of action for medical monitoring when the party seeking relief has yet to develop any identifiable physical injuries or symptoms. For the reasoning set forth below, we answer this question in the affirmative and reverse the trial court's Order Granting Final Judgment on the Pleadings.

The Plaintiffs filed a state-wide class action in equity against Defendants, manufacturers and sellers of Fenfluramine and Phentermine (Fen-Phen), much publicized pharmaceutical weight loss products. Although Plaintiffs currently have no physical injuries as a result of using these medicines, they claim that ingesting the combinations of these two drugs has placed them at a substantially increased risk of developing serious cardiac and circulatory ailments, including heart valve damage. As a result, Plaintiffs sought an *105 injunction requiring Defendants to fund a court supervised medical monitoring program which provides for medical testing, monitoring, and study of Plaintiffs and those similarly situated for conditions caused by their use of Fen-Phen. Plaintiffs contend that this monitoring is medically reasonable and necessary, and will allow Fen-Phen users to avoid or minimize damage. The Defendants filed a Motion for Judgment on the Pleadings, arguing that Florida does not recognize a pre-injury claim for future expenses of medical diagnosis. The trial court granted the motion and Plaintiffs appeal. Since we hold that, under certain prescribed circumstances, Florida does recognize a cause of action for future expenses for medical diagnosis, the order of the trial court is reversed.

One of the Defendants' chief contentions is that no cause of action can lie for medical monitoring because plaintiffs in such cases have yet to suffer any injury. Although it is true that plaintiffs in cases such as these have yet to suffer physical injuries, it is not accurate to say that no injury has arisen at all. Perhaps the best illustration of how an injury can arise without a physical injury, for medical monitoring purposes, is a hypothetical posed by the United States Court of Appeal for the District of Columbia in Friends for All Children, Inc. v. Lockheed Aircraft Corp.:

Jones is knocked down by a motorbike which Smith is riding through a red light. Jones lands on his head with some force. Understandably shaken, Jones enters a hospital where doctors recommend that he undergo a battery of tests to determine whether he has suffered any internal head injuries. The tests prove negative, but Jones sues Smith solely for what turns out to be the substantial cost of the diagnostic examinations.

746 F.2d 816, 825 (D.C.Cir.1984).

It is clear that in this example, Jones should be able to recover the cost of the various diagnostic treatments caused by Smith's negligence. It is less clear whether or not Jones should be able to recover for future medical expenses that have yet to arise. Although we do not think that plaintiffs should be able to recover lump sum damages in anticipation of future diagnostic expenses, we do think it entirely proper for a court of equity to create and supervise a fund for the purpose of monitoring the condition of plaintiffs when it has been shown that such monitoring is reasonably necessary. As the Friends for All Children court points out, injury is "`the invasion of any legally protected interest of another.'" See Id. at 826 (quoting RESTATEMENT (SECOND) OF TORTS § 7). One can hardly dispute that an individual has just as great an interest in avoiding expensive diagnostic examinations as in avoiding physical injury. See Id. Although one might suggest that plaintiffs should wait until after the expenses of monitoring have been incurred before a cognizable claim arises, such a holding would foreclose countless economically disadvantaged individuals from obtaining the supervision that they need, and, regardless of financial need, simply force the victims, rather than the wrongdoers, to initially bear these great expenses. Such a result is untenable in a court of equity.

In support of their position that no cause of action exists for medical monitoring absent a physical injury, Defendants cite to this court's decision in Eagle-Picher Indus., Inc. v. Cox, 481 So.2d 517 (Fla. 3d DCA 1985). In Eagle-Picher, we held that a plaintiff cannot recover for the enhanced risk that they will contract a disease. Id. at 520. Our holding today is in no way inconsistent with Eagle-Picher, as a claim for medical monitoring is wholly distinguishable from a claim for enhanced risk of disease. See Redland Soccer Club, Inc. v. Dep't. of the Army, 548 Pa. 178, 696 A.2d 137 (1997). As the court in Redland stated:

[A]n action for medical monitoring seeks to recover only the quantifiable costs of periodic medical examinations necessary *106 to detect the onset of physical harm, whereas an enhanced risk claim seeks compensation for the anticipated harm itself, proportionately reduced to reflect the chance that it will not occur....
... The injury in an enhanced risk claim is the anticipated harm itself. The injury in a medical monitoring claim is the cost of the medical care that will, one hopes, detect that injury. The former is inherently speculative because courts are forced to anticipate the probability of future injury. The latter is much less speculative because the issue for the jury is the less conjectural question of whether the plaintiff needs medical surveillance.

Id., 696 A.2d at 144. (quoting In re Paoli R.R. Yard PCB Litigation, 916 F.2d 829, 850-51 (3d Cir.1990)). Thus, our holding today does not stray from prior decisions of this court.

In further keeping with Eagle-Picher, we hold that plaintiffs in medical monitoring cases will not be precluded by the rule against splitting causes of action from bringing claims for whatever physical injuries they suffer if and when they arise. See Rosenthal v. Scott,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dougan v. Sikorsky Aircraft Corp.
337 Conn. 27 (Supreme Court of Connecticut, 2020)
CITY OF FORT LAUDERDALE v. WALTER HINTON
District Court of Appeal of Florida, 2019
Bell v. 3M Co.
344 F. Supp. 3d 1207 (D. Colorado, 2018)
Hanson v. Collins Electrical Co. CA1/1
California Court of Appeal, 2016
Tillman v. C.R. Bard, Inc.
96 F. Supp. 3d 1307 (M.D. Florida, 2015)
Exxon Mobil Corp. v. Albright
71 A.3d 30 (Court of Appeals of Maryland, 2013)
Exxon Mobil Corp. v. Ford
40 A.3d 514 (Court of Special Appeals of Maryland, 2012)
In re Welding Fume Products Liability Litigation
245 F.R.D. 279 (N.D. Ohio, 2007)
Meyer Ex Rel. Coplin v. Fluor Corp.
220 S.W.3d 712 (Supreme Court of Missouri, 2007)
Scott v. American Tobacco Co., Inc.
949 So. 2d 1266 (Louisiana Court of Appeal, 2007)
Paz v. Brush Engineered Materials, Inc.
949 So. 2d 1 (Mississippi Supreme Court, 2007)
Wyeth, Inc. v. Gottlieb
930 So. 2d 635 (District Court of Appeal of Florida, 2006)
Norwood v. Raytheon Co.
414 F. Supp. 2d 659 (W.D. Texas, 2006)
Henry v. Dow Chemical Company
701 N.W.2d 684 (Michigan Supreme Court, 2005)
Zehel-Miller v. Astrazenaca Pharmaceuticals, LP
223 F.R.D. 659 (M.D. Florida, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
750 So. 2d 103, 1999 WL 1221653, Counsel Stack Legal Research, https://law.counselstack.com/opinion/petito-v-ah-robins-co-inc-fladistctapp-1999.